Draft Amendment to New Drugs and Clinical Trials Rules, 2019: Bringing Antimicrobials Under 'New Drug' Regulation
UPSCPIBSource: PIB
1
Why in News
- The Union Ministry of Health and Family Welfare has proposed an amendment to the New Drugs and Clinical Trials Rules, 2019 through draft Gazette Notification G.S.R. 983 (E) dated 6th November.
- The amendment seeks to include 'antimicrobials' in the definition of 'New Drug' under Rule 2(1)(w)(v) of the said Rules.
- The draft notification invites objections and suggestions from stakeholders and the public before finalisation by the Central Government.
- The move is driven by concerns over antimicrobial resistance (AMR), a major global public health priority also highlighted in the G20 New Delhi Leaders' Declaration.
2
What is the issue
- Regulatory gap: Manufacturing licences for antimicrobial products were being granted without adequate regulatory scrutiny, including required bioavailability/bioequivalence and stability studies.
- Quality and safety risk: Absence of such assessments can affect the quality, safety and efficacy of antimicrobial products.
- AMR link: Substandard or ineffective antimicrobials can contribute to the development and spread of antimicrobial resistance, posing risks to patient safety.
- Policy framework: The proposed amendment brings antimicrobials within the regulatory framework applicable to new drugs under the New Drugs and Clinical Trials Rules, 2019.
- Institutional mechanism: Manufacturers would need permission from the Central Licensing Authority (CLA) before applying for a manufacturing licence from the State Licensing Authority (SLA).
- Stakeholders: The Union Ministry of Health and Family Welfare, Central Licensing Authority, State Licensing Authorities, manufacturers, and the public are key stakeholders in the consultation process.
- Global context: AMR is a major global public health concern requiring coordinated action, as underscored by the G20 New Delhi Leaders' Declaration through a One Health approach.
The full analysis is in the app
This page is the summary. The detailed analysis of this story covers:
What is the statusWhat are the challengesWhat measuresWhat lies aheadImportant Data PointsBackgroundKey Important PointsPrelims RelatedMains RelatedImportant WordsKey conceptsPrevious year questions
Open in Quorum IAS